News Overview

Operating performance was affected, with EBITDA declining 28.6% to ₹69.3 crore, from ₹97 crore in the corresponding year-ago quarter.

Asset quality also improved during the quarter, as the gross NPA ratio reduced to 1.74% from 1.80% in the last quarter.

The Board of Directors has recommended a final dividend of ₹25 per equity share for the year ended March 31, 2025.

Net profit increased to ₹446.4 crore from ₹427.8 crore in the last quarter and ₹393.2 crore for the same quarter year ago.

Quarterly Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) was ₹4,820 crore, a year-on-year growth of 32%.

The company also reported reduced total expenses of ₹1,088.20 crore in Q4 FY25 against ₹1,094.4 crore in Q4 FY24, thus leading to enhanced profitability

Consolidated net profit was at ₹3,711 crore in Q4 FY25, down from the same period last year.

The EBITDA for the quarter stood at ₹784.6 crore, much higher than the previous level.

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

Quarterly revenues of ₹40,674 crore trailed predicted ₹40,747 crore, yet arrived at a 6% sequential year-to-year better than last year's third-quarter ₹38,235 crore